- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00554489
Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
A Feasibility Study of a Physical Activity Intervention in Older Adult Inpatients With Acute Leukemia
RATIONALE: Physical activity sessions may help improve physical function, quality of life, and symptoms caused by chemotherapy in older patients with acute myelogenous leukemia.
PURPOSE: This clinical trial is studying how well physical activity works in improving quality of life in older patients with acute myelogenous leukemia undergoing chemotherapy.
Studieoversikt
Detaljert beskrivelse
OBJECTIVES:
Primary
- To test the feasibility of conducting a physical activity intervention in hospitalized older adults with acute myeloid leukemia (AML) undergoing induction or reinduction chemotherapy.
Secondary
- To obtain preliminary data regarding the effectiveness of a physical activity intervention on physical function, quality of life, and treatment-related symptoms in these patients.
OUTLINE: Patients undergo a baseline evaluation in week 1 focusing on basic demographics, health, physical function and quality-of-life assessments. These assessments include the Short Physical Performance Battery (SPPB); the Hand Grip Test of Muscular Strength; the Demographics and Physical Activity History; the Functional Assessment of Cancer Therapy (FACT-Leu); the Distress Thermometer; the Short-form Positive Affect Schedule (PANAS-SF); the Satisfaction with Life Scale (SWL); the FAST-23 Disability Measure; the Center for Epidemiologic Studies Depression Scale Short Form (CES-D); the Self-efficacy for Physical Activity Scale; the Intervention Feedback Form; and the Pre-Post Session Ratings. Some medical data may be obtained from the patient's medical record to assist in these assessments.
Beginning in weeks 2-5, patients undergo a 30-minute orientation to the exercise sessions that will be tailored to individual needs and abilities. Patients undergo a 30- to 45-minute group physical activity session twice a week, and a supervised individual session following the same format as the group session, once a week for 4 weeks. After completion of the physical activity intervention, patients complete an activities packet and repeat the physical function and quality of life assessments in weeks 5-6 and again upon readmission for consolidation therapy in weeks 9-13 .
After completion of study intervention, patients are followed for 4 months.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
- Histologically confirmed acute myeloid leukemia (AML) by WHO criteria
- Planning to undergo induction or reinduction chemotherapy
- Inpatient status at Wake Forest University Baptist Medical Center
- Must not require intensive care unit support
PATIENT CHARACTERISTICS:
- Able to understand English
- Medical eligibility confirmed with Leukemia Service Attending
- Ambulatory or able to walk with a cane
- No hemodynamic instability
- No acute thrombosis within the past 7 days
- No active ischemia within the past 7 days
- No uncontrolled pain
- Must have < 3 incorrect responses on the Pfeiffer Mental Status Exam
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Percentage of adults 50 years of age or older admitted for induction or reinduction chemotherapy for acute myeloid leukemia (AML) who are eligible for the study
Tidsramme: day 1
|
day 1
|
|
Percentage of eligible patients recruited into the study
Tidsramme: day 1
|
day 1
|
|
Number and frequency of reported barriers to eligibility and enrollment
Tidsramme: day 1
|
day 1
|
|
Percentage of study participants who successfully completed the physical and the psychosocial measures
Tidsramme: week 13
|
week 13
|
|
Record barriers to completion of the physical activity program
Tidsramme: week 13
|
week 13
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Physical function as measured by the Short Physical Performance Battery (SPPB)
Tidsramme: week 13
|
week 13
|
|
Quality of Life as measured with the Distress Thermometer
Tidsramme: week 13
|
week 13
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Heidi D. Klepin, MD, Wake Forest University Health Sciences
- Hovedetterforsker: Shannon Mihalko, PhD, Wake Forest University Health Sciences
- Studiestol: Suzanne C. Danhauer, PhD, Wake Forest University Health Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- akutt myeloid leukemi hos voksne med 11q23 (MLL) abnormiteter
- akutt myeloid leukemi hos voksne med inv(16)(p13;q22)
- akutt myeloid leukemi hos voksne med t(15;17)(q22;q12)
- akutt myeloid leukemi hos voksne med t(16;16)(p13;q22)
- akutt myeloid leukemi hos voksne med t(8;21)(q22;q22)
- tilbakevendende akutt myeloid leukemi hos voksne
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CDR0000573938
- CCCWFU-98107
- IRB00003355
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .